PT-141 dosage nasal spray is not FDA-approved, and reported intranasal amounts vary widely. See how researchers, men, and women compare dosing and risks.
There is no FDA-approved PT-141 nasal spray, so no official nasal dosage exists. The only approved form of PT-141 (bremelanotide) is a 1.75 mg subcutaneous injection sold as Vyleesi, and it is approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Intranasal amounts reported in older research and online are far larger and vary widely, which is why clinicians treat nasal use as experimental.
What PT-141 Is and Why People Use a Nasal Spray
PT-141 is a synthetic peptide that activates melanocortin receptors in the brain, mainly MC4R. It acts on central desire and arousal pathways rather than on blood flow, which is the main reason it is described as different from drugs like sildenafil.
A nasal spray appeals to people who want to avoid injections, travel light, or adjust doses more easily. Vendors often sell the peptide as a "research chemical" along with a spray bottle and mixing supplies.
None of that changes its regulatory status. PT-141 nasal spray is not FDA-approved for human use in the United States, and online products are not verified for purity, sterility, or how much peptide the bottle actually contains.
Reported PT-141 Nasal Spray Dosages
Older intranasal bremelanotide studies used amounts much larger than the injectable dose, because only a small fraction of an intranasal dose reaches the bloodstream. Community reports then repeated those numbers without the study context.
| Form | Reported or studied amount | Frequency guidance | FDA status |
|---|---|---|---|
| Subcutaneous injection (Vyleesi) | 1.75 mg | Maximum one dose per 24 hours; maximum 8 doses per month | Approved for premenopausal women with HSDD |
| Nasal spray (research use) | Roughly 10 to 20 mg per dose in older intranasal trials; online reports range from about 5 mg to 20 mg | Not established; most reports describe no more than one dose per day | Not approved |
| Other research routes (sublingual, topical, oral) | Highly variable | Not established | Not approved |
No two versions of a pt-141 nasal spray dosage chart match each other, and that disagreement is a clear sign the numbers come from anecdotes rather than controlled trials. A dose copied from a forum post may also reflect a different peptide concentration than the bottle in front of you.
Men vs. Women: Does the Nasal Dose Change?
Bremelanotide was approved only for premenopausal women, so use in men is entirely off-label. No nasal version has been reviewed for either group.
People searching pt-141 nasal spray dosage for men or pt-141 nasal spray dosage for women often expect two clearly different numbers. The published intranasal research used broadly similar amounts in both groups, and body weight, cardiovascular health, and nasal absorption usually matter more than sex alone.
Absorption can also shift from one session to the next depending on nasal congestion, allergies, recent use of decongestant sprays, and spray technique. That inconsistency is one of the main reasons nasal dosing is hard to standardize.
Timing, Frequency, and Duration
- The approved injectable is given about 45 minutes before anticipated sexual activity.
- Intranasal reports describe onset roughly 15 to 60 minutes after use, with effects lasting several hours.
- The injectable label limits use to one dose per 24 hours and no more than eight doses per month.
- There is no safety data supporting more frequent nasal use, so the same ceiling is a sensible reference point.
- Nasal and injectable forms should not be combined on the same day.
Side Effects and Safety
Bremelanotide's most common side effects are nausea, flushing, headache, and vomiting. Some people also report nasal burning or irritation with spray formulations.
The drug can raise blood pressure and lower heart rate temporarily, and it is contraindicated in people with uncontrolled hypertension or known cardiovascular disease. Repeated use has also been linked to focal hyperpigmentation, including darkening of the gums, face, or breasts.
Unregulated nasal products carry additional risk. Peptide identity, concentration, and sterility are usually unverified, and solutions without a preservative can grow bacteria once opened. Anyone considering PT-141 in any form should talk with a healthcare professional first, especially if they take blood pressure medication or have heart disease.
Why Online Dose Numbers Vary So Much
Threads that rank for pt-141 nasal spray dosage reddit often mix injectable numbers with nasal numbers, and few mention whether the product was third-party tested. Vendor pages copy each other, so one inaccurate figure can spread across dozens of sites.
Instructions for how to make pt-141 nasal spray are easy to find, and most describe mixing lyophilized powder with bacteriostatic water and transferring it into a spray bottle. Homemade solutions cannot be made sterile, the final concentration is rarely measured, and peptides degrade when stored or handled incorrectly.
Compounding pharmacies can prepare custom formulations with a prescription, and regulators have issued warnings about compounded peptides sold without one. That distinction matters far more than any dose chart posted online.
Bottom Line
- PT-141 is FDA-approved only as a 1.75 mg subcutaneous injection for premenopausal women with hypoactive sexual desire disorder.
- No nasal spray form of PT-141 is FDA-approved, and no official nasal dosage exists.
- Older intranasal studies used roughly 10 to 20 mg per dose, but those amounts are not a validated or safe self-dosing recommendation.
- Blood pressure changes and hyperpigmentation are the two risks most often overlooked by people ordering research-grade peptides online.
- Anyone using PT-141 should do so under medical supervision and never exceed one dose in 24 hours.
Frequently Asked Questions
Is PT-141 nasal spray FDA-approved?
No. The FDA has approved bremelanotide only as a 1.75 mg subcutaneous injection sold as Vyleesi, for premenopausal women with hypoactive sexual desire disorder. No nasal spray version of PT-141 has been reviewed or approved for human use in the United States.
What is the typical PT-141 nasal spray dosage?
There is no established nasal dosage because the form is not approved. Older intranasal studies used much larger amounts than the injectable dose, generally in the range of 10 to 20 mg per administration, while online reports vary from about 5 mg to 20 mg. Those figures are not a clinical recommendation.
How long before sex should you use PT-141 nasal spray?
Reports usually describe using it about 15 to 60 minutes beforehand, and the approved injectable is given roughly 45 minutes before activity. Effects are commonly reported to last several hours. A dose should not be repeated within 24 hours.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.